7635-29-2

Basic information

• Product Name: H-DL-TYR(ME)-OH
• Synonyms: H-DL-PHE(4-MEO)-OH;H-DL-PHE(4-OME)-OH;H-4-METHOXY-DL-PHE-OH;DL-4-MeO-Phe-OH;DL-H-Tyr(Me)-OH;DL-3-(p-Methoxyphenyl)alanine;DL-o-Methyltyrosine;NSC 101132
• CAS NO: 7635-29-2
• Molecular Formula: C₁₀H₁₃NO₃
• Molecular Weight: 195.22
• Product Categories: Amino Acids & Derivatives;Aromatics
• Mol File: 7635-29-2.mol
• Article Data: 10

Chemical Properties

• Melting Point: 285-287 °C (decomp)
• Boiling Point: 350.6 °C at 760 mmHg
• Flash Point: 165.8 °C
• Appearance: /
• Density: 1.209 g/cm³
• Storage Temp.: Store at RT.
• PKA: 2.24±0.10(Predicted)
• CAS DataBase Reference: H-DL-TYR(ME)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: H-DL-TYR(ME)-OH(7635-29-2)
• EPA Substance Registry System: H-DL-TYR(ME)-OH(7635-29-2)

Safety Data

• Hazardous Substances Data: 7635-29-2(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

Racemic tyrosine derivative.

Upstream product

• 114461-07-3 3-(4-Methoxy-phenyl)-2-{[1-phenyl-meth-(E)-ylidene]-amino}-propionic acid ethyl ester 
• 154199-10-7 [1-Cyano-2-(4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 7440-44-0 pyrographite 
• 53612-87-6 2-acetylamino-2-(4-methoxybenzyl)malonic acid diethyl ester 
• 214057-97-3 2-[(E)-Hydroxyimino]-3-(4-methoxy-phenyl)-propionic acid ethyl ester 
• 36600-75-6 2-(4-methoxy-benzyl)-3-oxo-butyric acid ethyl ester 
• 824-94-2 p-methoxybenzyl chloride 
• 154199-09-4 2-Cyano-3-(4-methoxy-phenyl)-propionyl azide 
• 154198-90-0 (E)-3-p-anisyl-2-cyano-2-propenoyl azide 
• 27888-23-9 (E)-3-p-anisyl-2-cyano-2-propenoyl chloride 
• 14378-08-6 (E)-2-cyano-3-(4-methoxyphenyl)acrylic acid 
• 187836-07-3 methyl (N-benzoyl)-4'-methoxyphenylalaninate 
• 57427-78-8 (4Z)-4-(4-methoxybenzylidene)-2-phenyl-oxazolin-5-one 
• 34996-89-9 2-benzoylamino-3-(4-methoxy-phenyl)-propionic acid 

Downstream Products

• 7479-01-8 O-methyl-tyrosine methyl ester; hydrochloride 
• 77128-72-4 N-(9-Fluorenylmethyloxy)carbonyl-O-methyl-L-tyrosine 
• 78700-15-9 (S)-2-[(S)-2-((S)-2-tert-Butoxycarbonylamino-propionyloxy)-3-methyl-butyrylamino]-3-(4-methoxy-phenyl)-propionic acid 
• 82283-48-5 2-Chloromethyl-4-[1-(4-methoxy-phenyl)-meth-(Z)-ylidene]-4H-oxazol-5-one 
• 70601-62-6 (D)-N-acetyl-4-methoxy-phenylalanine 
• 4368-01-8 3-hydroxy-4-methoxy-phenylalanine 
• 56876-09-6 N-phthaloyl-O-methyltyrosine 
• 82283-60-1 (Z)-2-(2-Amino-acetylamino)-3-(4-methoxy-phenyl)-acrylic acid 
• 82283-55-4 (Z)-2-(2-Chloro-acetylamino)-3-(4-methoxy-phenyl)-acrylic acid 
• 39878-65-4 (R)-β-(4-methoxyphenyl)alanine 
• 1427284-62-5 C₁₈H₁₇NO₃ 
• 55456-41-2 L-p-Methoxyphenylalaninbenzylester 
• 55895-90-4 (±)-ethyl 2-amino-3-(4-methoxyphenyl)propanoate 

Relevant articles and documents

Organocatalytic Enantioselective Addition of α-Aminoalkyl Radicals to Isoquinolines

With a dual organocatalytic system involving a chiral phosphoric acid and a dicyanopyrazine-derived chromophore (DPZ) photosensitizer and under the irradiation with visible light, an enantioselective Minisci-type addition of α-amino acid-derived redox-active esters (RAEs) to isoquinolines has been developed. A variety of prochiral α-aminoalkyl radicals generated from RAEs were successfully introduced on isoquinolines, providing a range of valuable α-isoquinoline-substituted chiral secondary amines in high yields with good to excellent enantioselectivities.

Immunomodulatory peptides

The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.

[B]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS

The invention relates to a compound which is [b]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating diseases, including, but not limited to, methods of preventing or inhibiting joint cartilage damage and preventing or treating diseases characterized by joint cartilage damage, joint inflammation, or joint pain. The [b]-fused bicyclic proline derivatives are compounds of Formula I as described above. Diseases characterized by joint cartilage damage or joint pain include, for example, osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is also characterized by joint inflammation. This invention also relates to methods of synthesizing and preparing the [b]-fused bicyclic proline derivatives, or a pharmaceutically acceptable salt thereof.